In highly malignant 4T1 breast tumors, posttreatment supplementation with sEVs released after therapy could effectively orchestrate the differentiation of MDSCs and monocytes into macrophages and CD4+ T cells toward the Th1 subtype; thus, enhancing the efficacy of cryo-thermal therapy. Here, CD4 is linked to breast neoplasm.